Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96AC6
UPID:
KIFC2_HUMAN
Alternative names:
-
Alternative UPACC:
Q96AC6; E9PHB2; Q96NN6
Background:
Kinesin-like protein KIFC2 is implicated in microtubule-dependent retrograde axonal transport, playing a pivotal role in neuronal function. It is believed to act as the motor for the transport of multivesicular body (MVB)-like organelles in dendrites, a process critical for maintaining cellular health and function.
Therapeutic significance:
Understanding the role of Kinesin-like protein KIFC2 could open doors to potential therapeutic strategies, offering new avenues for addressing neurological disorders by targeting the mechanisms of axonal transport and organelle distribution.